146 related articles for article (PubMed ID: 14726871)
1. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects.
Smit JV; de Sévaux RG; Blokx WA; van de Kerkhof PC; Hoitsma AJ; de Jong EM
J Am Acad Dermatol; 2004 Feb; 50(2):189-96. PubMed ID: 14726871
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical effects of temporary cessation of long-term acitretin treatment in keratinocytic intraepidermal neoplasia of renal transplant recipients.
Blokx WA; Smit JV; de Wilde PC; van de Kerkhof PC; Ruiter DJ; de Jong EM
Arch Dermatol; 2003 May; 139(5):671-3. PubMed ID: 12756113
[No Abstract] [Full Text] [Related]
3. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin.
de Sévaux RG; Smit JV; de Jong EM; van de Kerkhof PC; Hoitsma AJ
J Am Acad Dermatol; 2003 Sep; 49(3):407-12. PubMed ID: 12963902
[TBL] [Abstract][Full Text] [Related]
4. Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin.
Carneiro RV; Sotto MN; Azevedo LS; Ianhez LE; Rivitti EA
Clin Transplant; 2005 Feb; 19(1):115-21. PubMed ID: 15659144
[TBL] [Abstract][Full Text] [Related]
5. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study.
Bavinck JN; Tieben LM; Van der Woude FJ; Tegzess AM; Hermans J; ter Schegget J; Vermeer BJ
J Clin Oncol; 1995 Aug; 13(8):1933-8. PubMed ID: 7636533
[TBL] [Abstract][Full Text] [Related]
6. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation.
McNamara IR; Muir J; Galbraith AJ
J Heart Lung Transplant; 2002 Nov; 21(11):1201-5. PubMed ID: 12431493
[TBL] [Abstract][Full Text] [Related]
7. Aggressive undifferentiated squamous cell carcinoma in an immunosuppressed patient after kidney transplantation.
Haustein UF; Paasch U
J Dtsch Dermatol Ges; 2005 Jan; 3(1):44-6. PubMed ID: 16353749
[TBL] [Abstract][Full Text] [Related]
8. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
[TBL] [Abstract][Full Text] [Related]
9. Use of acitretin for the skin complications in renal transplant recipients.
Yuan ZF; Davis A; Macdonald K; Bailey RR
N Z Med J; 1995 Jun; 108(1002):255-6. PubMed ID: 7617333
[TBL] [Abstract][Full Text] [Related]
10. High sun protection factor sunscreens in the suppression of actinic neoplasia.
Naylor MF; Boyd A; Smith DW; Cameron GS; Hubbard D; Neldner KH
Arch Dermatol; 1995 Feb; 131(2):170-5. PubMed ID: 7857113
[TBL] [Abstract][Full Text] [Related]
11. Acitretin for hypertrophic lichen planus-like reaction in a burn scar.
Kossard S; Artemi P
Arch Dermatol; 2000 May; 136(5):591-4. PubMed ID: 10815851
[No Abstract] [Full Text] [Related]
12. [Actinic keratoses].
Babilas P; Landthaler M; Szeimies RM
Hautarzt; 2003 Jun; 54(6):551-60; quiz 561-2. PubMed ID: 12858853
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Brown VL; Atkins CL; Ghali L; Cerio R; Harwood CA; Proby CM
Arch Dermatol; 2005 Aug; 141(8):985-93. PubMed ID: 16103328
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients.
Rook AH; Jaworsky C; Nguyen T; Grossman RA; Wolfe JT; Witmer WK; Kligman AM
Transplantation; 1995 Mar; 59(5):714-9. PubMed ID: 7886798
[TBL] [Abstract][Full Text] [Related]
16. Acitretin as cancer chemoprophylaxis in a renal transplant recipient.
Vandeghinste N; De Bersaques J; Geerts ML; Kint A
Dermatology; 1992; 185(4):307-8. PubMed ID: 1477430
[TBL] [Abstract][Full Text] [Related]
17. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin.
McKenna DB; Murphy GM
Br J Dermatol; 1999 Apr; 140(4):656-60. PubMed ID: 10233316
[TBL] [Abstract][Full Text] [Related]
18. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients.
George R; Weightman W; Russ GR; Bannister KM; Mathew TH
Australas J Dermatol; 2002 Nov; 43(4):269-73. PubMed ID: 12423433
[TBL] [Abstract][Full Text] [Related]
19. Serum Sirolimus Level Elevation Induced by Acitretin: Report of a Novel Drug-Drug Interaction.
Rossi AM; Hibler BP; Johnson-Jahangir H
J Drugs Dermatol; 2015 Jul; 14(7):747-9. PubMed ID: 26151793
[TBL] [Abstract][Full Text] [Related]
20. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients.
De Graaf YG; Euvrard S; Bouwes Bavinck JN
Dermatol Surg; 2004 Apr; 30(4 Pt 2):656-61. PubMed ID: 15061851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
